SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024.
Dr. Tse, M.D. & Ph.D. earned Doctor of Medicine and Doctor of Biochemistry and Molecular Biology degrees from the University of Southern California. Prior to joining Adlai Nortye, Dr. Tse served as the Chief Scientific Officer, Senior Vice President, Head of Research and Early Clinical Development, and Head of CMC at CStone Pharmaceuticals, at which he provided strategic leadership and oversight to the research, early clinical development, and CMC aspects of the entire CStone's pipeline. Before joining CStone, Dr. Tse held leadership positions in multinational companies, including Merck (known as MSD outside of US and Canada) and Daiichi-Sankyo where he managed the advancement of innovative oncology drugs across all stages of development, encompassing various modalities, including small molecule targeted therapies, mono- and multi-specific antibodies, ADCs, and cancer vaccines. Prior to his career in the industry, Dr. Tse served as a faculty member at the Memorial Sloan Kettering Cancer Center in New York.
"We are very pleased to have Dr. Tse join our senior leadership team," said Carsten Lu, CEO and Chairman of Adlai Nortye. "Archie brings a wealth of knowledge in the field of bridging preclinical and clinical phases to improve overall success of drug development. His addition to our team will help us continue our pursuit of bringing novel therapies to cancer patients globally."
"I am excited to join Adlai Nortye and help advance the Company's mission of transforming deadly cancer into a chronic and eventually curable disease," said Dr. Tse. "I'm keen to leveraging my experiences with the outstanding team at Adlai Nortye and unlock the full potential of our pipeline."
新加坡和新澤西州北不倫瑞克省以及中國杭州，2024年3月29日（GLOBE NEWSWIRE）——專注於創新癌症療法開發的臨床階段生物技術公司阿德萊北泰有限公司（納斯達克股票代碼：ANL）（“公司” 或 “Adlai Nortye”）今天宣佈任命謝奇博士爲研發主管，向Adlai首席執行官兼董事長陸嘉誠先生彙報 Nortye，自 2024 年 3 月 29 日起生效。
謝博士，醫學博士和博士在南加州大學獲得醫學博士學位以及生物化學和分子生物學博士學位。在加入Adlai Nortye之前，謝博士曾在cStone製藥擔任首席科學官、高級副總裁、研究和早期臨床開發主管以及CMC負責人，在此期間，他對整個cStone產品線的研究、早期臨床開發和CMC方面提供了戰略領導和監督。在加入cStone之前，謝博士曾在包括默沙東（在美國和加拿大以外被稱爲默沙東）和第一三共在內的跨國公司擔任領導職務，在那裏他管理創新腫瘤藥物開發的各個階段，涵蓋各種模式，包括小分子靶向療法、單特異性和多特異性抗體、ADC和癌症疫苗。在從事該行業之前，謝博士曾在紐約紀念斯隆·凱特琳癌症中心擔任教員。
Adlai Nortye首席執行官兼董事長卡斯滕·盧說：“我們很高興謝博士加入我們的高級領導團隊。”“Archie在連接臨床前和臨床階段以提高藥物開發的整體成功率方面擁有豐富的知識。他加入我們的團隊將幫助我們繼續努力爲全球癌症患者提供新療法。”
謝博士說：“我很高興加入Adlai Nortye，幫助推進公司的使命，將致命的癌症轉變爲一種慢性並最終可以治癒的疾病。”“我渴望利用我在Adlai Nortye優秀團隊中的經驗，釋放我們產品線的全部潛力。”
